Hepatocellular carcinoma (HCC) frequently occurs in patients with cirrhosis and chronic liver
disease due to any aetiology and is associated with increased liver-related mortality …

Background: Chronic hepatitis B and C infections represent major risk factors for the
development of hepatocellular carcinoma (HCC). Recently, the management of patients with …

Introduction: Clinical trials in hepatocellular carcinoma (HCC) exhibit a high degree of
heterogeneity. These heterogeneities may lead to unexpected results among clinical trials …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the main
cause of cancer-related death worldwide. The available treatment options for HCC include …

Curative treatments, including liver transplantation, surgical resection and percutaneous
treatments, are the recommended therapies in BCLC-0 (Barcelona Clinic of Liver Cancer) or …

Objective: To review the history of development of systemic therapy for advanced
hepatocellular carcinoma (HCC). Data Sources: Published clinical trials of single-agent …

Management of hepatocellular carcinoma (HCC) has been continuously evolving during
recent years. HCC is a worldwide clinical and social issue and typically a complicates …

Hepatocellular carcinoma (HCC) is a major healthcare problem with an increasing
incidence worldwide and a poor prognosis despite the application of screening protocols …

Simple Summary Hepatocellular carcinoma is the second leading cause of cancer-related
deaths and the seventh most common cancer worldwide. Although there have been rapid …